CLINICAL DEVELOPMENT AND OPTION AGREEMENTClinical Development and Option Agreement • August 4th, 2016 • Medgenics, Inc. • Biological products, (no disgnostic substances) • New York
This Clinical Development and Option Agreement (this “Agreement”) is made and entered into effective as of this 6th day of June, 2016 (the “CDOA Effective Date”), by and between Kyowa Hakko Kirin Co., Ltd. (“KHK”), having a place of business at 1-6-1, Otemachi, Chiyoda-ku, Tokyo 100-8185, Japan, and Medgenics, Inc. (“Medgenics”), having an address at 435 Devon Park Drive, Building 700, Wayne, PA 19087, U.S.A. Each of KHK and Medgenics may be referred to herein individually as a “Party” and together as the “Parties.”
CERTAIN INFORMATION IDENTIFIED WITH THE MARK “(***)”, “(***%***)” AND “(***$***)” HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE SUCH INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED...Clinical Development and Option Agreement • August 6th, 2020 • Cerecor Inc. • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”), effective as of the Effective Date (as defined in Section 2.1), is by and between Kyowa Kirin Co., Ltd., a company organized and existing under the laws of the Japan and having its principal office at 1-9-2, Otemachi, Chiyoda-ku, Tokyo 100-0004, Japan and formerly known as Kyowa Hakko Kirin Co., Ltd. (“KKC”), and Aevi Genomic Medicine, LLC, a Delaware limited liability company and successor to Medgenics, Inc., a Delaware corporation (“AEVI”). KKC and AEVI may each be referred to herein individually as a “Party” and collectively as the “Parties.”
